Cipla is lined up to copy 9 of the blockbuster drugs on this tracker, which earned $71.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Cipla's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Aug 2026 | $2.7B |
| Cabometyx | Exelixis | Generic | 2031 | Settled; license from 1 Jan 2031 | $2.1B |
| Lynparza | AstraZeneca / Merck | Generic | 2027 | Generic filed; in litigation | $3.3B |
| Otezla | Amgen | Generic | 2028 | Settled in 2021, terms confidential | $2.3B |
| Descovy | Gilead | Generic | 2031 | Settled 2022; new challenge, sued Feb 2026 | $2.8B |
| Calquence | AstraZeneca | Generic | 2032 | In litigation; trial Apr 2027 | $3.5B |
| Biktarvy | Gilead | Generic | 2036 | Settled Oct 2025 | $14.3B |
| Keytruda | Merck | Biosimilar | 2028 | US partnership signed, Sep 2026 | $31.7B |
Company facts: TradingView. Each drug page lists sources for these entries. Brand sales show the size of the market, not Cipla's share of it.